Piramal Pharma Solutions (PPS) has officially unveiled a state-of-the-art microbiology laboratory at its sterile injectable manufacturing facility in Lexington, Kentucky. This launch marks a pivotal milestone in the company’s ongoing $85 million investment project, aimed at bolstering U.S.-based commercial-scale production capabilities and significantly improving operational throughput for its global client base.
The new laboratory, which received conditional approval for its sterility testing suite and was cleared for routine Good Manufacturing Practice (GMP) operations on September 11, 2026, serves as the first major component of the broader Lexington facility expansion to reach completion. While this wing is already operational, the site’s full manufacturing expansion is currently on track to come online by late 2027.
The expansion is substantial in both scale and technology. By more than tripling the site’s existing microbiology testing footprint, PPS has effectively resolved previous spatial constraints, allowing for more fluid laboratory workflows. The facility now features three high-capacity biosafety cabinets, enabling concurrent testing and a meaningful reduction in sample queue times. Furthermore, the consolidation of all incubators within the new space has centralized testing activities, enhancing both monitoring oversight and laboratory accessibility.
Central to the facility’s technological upgrade is a dedicated sterility testing suite. Moving from a non-classified environment to a controlled Grade C background, the lab now houses a fully integrated, Grade A sterility testing isolator. This advanced equipment effectively doubles the site’s total sterility testing capacity, allowing for the simultaneous processing of multiple samples. With the capability to support both open and closed filtration methods, the isolator offers the versatility required to handle diverse product testing needs. Additionally, the integration of specialized pass-throughs ensures that samples can be transferred directly from the manufacturing floor to the laboratory, significantly mitigating contamination risks and protecting product integrity.
Nathan Richardson, VP and Site Head at PPS Lexington, underscored the strategic importance of these improvements. “By enhancing sterility testing and microbiological quality capabilities, we are further strengthening our ability to support clients with high-quality, reliable, and responsive services throughout the product life cycle,” Richardson stated.
The impact of this expansion is expected to be immediate for partners moving programs from clinical phases toward commercialization. PPS anticipates that the new infrastructure will reduce overall testing turnaround times by as much as 50%. This acceleration will facilitate faster batch releases and alleviate production bottlenecks. By reinforcing its contamination control and sterility assurance protocols, PPS is positioning its Lexington site to absorb increased commercial-scale demand while simultaneously reducing supply chain risks for its customers. As the industry continues to prioritize speed to market without compromising quality, this investment underscores PPS’s commitment to maintaining a robust, future-ready infrastructure in the United States.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
